FTH: Baird Initiates
Baird initiates coverage on Faeth Therapeutics with Outperform rating and $57 price target
Baird analyst Jack Allen initiates coverage on Faeth Therapeutics (NASDAQ: FTH ) with a Outperform rating and announces Price Target of $57.